NASDAQ:EMBC Embecta (EMBC) Stock Price, News & Analysis $3.32 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.33 +0.01 (+0.42%) As of 05/22/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Embecta Stock (NASDAQ:EMBC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Embecta alerts:Sign Up Key Stats Today's Range$3.23▼$3.4150-Day Range$2.90▼$9.7852-Week Range$2.77▼$15.55Volume1.77 million shsAverage Volume3.70 million shsMarket Capitalization$196.98 millionP/E Ratio1.75Dividend Yield18.07%Price Target$11.00Consensus RatingStrong Sell Company Overview Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes. The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices. These products are designed to support patients across the spectrum of diabetes management, from intensive insulin therapy to routine self-testing and continuous glucose monitoring systems. Embecta serves customers in more than 100 countries through a network of direct and indirect distribution channels that include hospitals, clinics, retail pharmacies and e-commerce platforms. The company maintains a global footprint with manufacturing and distribution sites strategically located across North America, Europe and the Asia-Pacific region to ensure supply continuity and responsiveness to regional regulatory requirements. Embecta is led by President and Chief Executive Officer Anthony J. Parker, whose leadership team leverages deep expertise in medical technology to drive innovation and expand the company’s product pipeline. Going forward, Embecta aims to enhance patient outcomes by advancing next-generation insulin delivery systems and digital health integrations that support personalized diabetes management. AI Generated. May Contain Errors. Read More Embecta Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreEMBC MarketRank™: Embecta scored higher than 80% of companies evaluated by MarketBeat, and ranked 123rd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingStrong Sell Consensus RatingEmbecta has received a consensus rating of Strong Sell. The company's average rating score is 1.40, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 3 sell ratings.Upside PotentialEmbecta has a consensus price target of $11.00, representing about 231.3% upside from its current price of $3.32.Amount of Analyst CoverageEmbecta has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Embecta's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.02% Earnings GrowthEarnings for Embecta are expected to grow by 8.02% in the coming year, from $1.62 to $1.75 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 1.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 1.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.28.Read more about Embecta's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.33% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 8.52.Change versus previous monthShort interest in Embecta has recently increased by 4.29%, indicating that investor sentiment is decreasing. Dividend3.3 / 5Dividend StrengthStrong Dividend LeadershipEmbecta is a leading dividend payer. It pays a dividend yield of 18.07%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 31.58%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 34.29% next year. This indicates that Embecta will be able to sustain or increase its dividend.Read more about Embecta's dividend. News and Social Media1.7 / 5News Sentiment-0.22 News SentimentEmbecta has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Embecta this week, compared to 3 articles on an average week.Search Interest24 people have searched for EMBC on MarketBeat in the last 30 days. This is an increase of 2,300% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have not sold or bought any company stock.Percentage Held by Insiders1.30% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Embecta's insider trading history. Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EMBC Stock News HeadlinesEmbecta (EMBC) Hit With A Sharp Target Cut As Medtech Sentiment Weakens3 minutes ago | finance.yahoo.comEmbecta Corp. (NASDAQ:EMBC) Receives $11.00 Average PT from AnalystsMay 23 at 4:02 AM | americanbankingnews.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 24 at 1:00 AM | Porter & Company (Ad)EMBC SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsMay 21 at 8:00 PM | businesswire.comEmbecta Corp. (EMBC) Securities Fraud Investigation - Levi & KorsinskyMay 20, 2026 | prnewswire.comEmbecta (NASDAQ:EMBC) Price Target Lowered to $3.00 at Bank of AmericaMay 19, 2026 | americanbankingnews.comEmbecta (EMBC) price target decreased by 24.00% to 12.92May 16, 2026 | msn.comEmbecta faces US reset as CEO bets on GLP-1, Owen Mumford diversificationMay 16, 2026 | msn.comSee More Headlines EMBC Stock Analysis - Frequently Asked Questions How have EMBC shares performed this year? Embecta's stock was trading at $11.88 at the beginning of 2026. Since then, EMBC shares have decreased by 72.1% and is now trading at $3.32. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) posted its earnings results on Tuesday, May, 5th. The company reported $0.27 earnings per share for the quarter, missing analysts' consensus estimates of $0.42 by $0.15. The business's revenue for the quarter was down 14.4% on a year-over-year basis. Read the conference call transcript. Who are Embecta's major shareholders? Top institutional investors of Embecta include SG Americas Securities LLC (1.75%), Dimensional Fund Advisors LP (1.58%), Bank of New York Mellon Corp (1.39%) and Walleye Capital LLC (1.34%). Insiders that own company stock include Devdatt Kurdikar, David F Melcher, Jacob Elguicze, Jeffrey Z Mann and Milton Mayo Morris. View institutional ownership trends. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Embecta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Embecta investors own include Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Record date for 3/17 Dividend2/27/2026Ex-Dividend for 3/17 Dividend2/27/2026Dividend Payable3/17/2026Last Earnings5/05/2026Today5/24/2026Record date for 6/15 Dividend5/28/2026Ex-Dividend for 6/15 Dividend5/28/2026Dividend Payable6/15/2026Next Earnings (Estimated)8/06/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 EMBC's financial health is in the Red zone, according to TradeSmith. EMBC has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryMedical Equipment Current SymbolNASDAQ:EMBC CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees1,850Year Founded2022Price Target and Rating Average Price Target for Embecta$11.00 High Price Target$25.00 Low Price Target$3.00 Potential Upside/Downside+231.3%Consensus RatingStrong Sell Rating Score (0-4)1.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$1.90 Trailing P/E Ratio1.75 Forward P/E Ratio2.05 P/E GrowthN/ANet Income$95.40 million Net Margins10.73% Pretax Margin16.27% Return on Equity-23.96% Return on Assets14.12% Debt Debt-to-Equity RatioN/A Current Ratio2.46 Quick Ratio1.68 Sales & Book Value Annual Sales$1.08 billion Price / Sales0.18 Cash Flow$4.00 per share Price / Cash Flow0.83 Book Value($10.55) per share Price / Book-0.31Miscellaneous Outstanding Shares59,330,000Free Float58,557,000Market Cap$196.98 million OptionableOptionable Beta1.09 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:EMBC) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredJune 12: Elon Musk’s “Day-One Retirement Plan.”SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
